Symbol="SABS"
AssetType="Common Stock"
Name="SAB Biotherapeutics Inc"
Description="SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts."
CIK="1833214"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="2100 EAST 54TH STREET NORTH, SIOUX FALLS, SD, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="31810100"
EBITDA="-25994734"
PERatio="None"
PEGRatio="None"
BookValue="0.377"
DividendPerShare="0"
DividendYield="0"
EPS="-0.56"
RevenuePerShareTTM="0.136"
ProfitMargin="0"
OperatingMarginTTM="-4.604"
ReturnOnAssetsTTM="-0.39"
ReturnOnEquityTTM="-1.027"
RevenueTTM="6417200"
GrossProfitTTM="-12534332"
DilutedEPSTTM="-0.56"
QuarterlyEarningsGrowthYOY="-0.6"
QuarterlyRevenueGrowthYOY="-0.987"
AnalystTargetPrice="2.53"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="1.506"
PriceToBookRatio="1.35"
EVToRevenue="1.206"
EVToEBITDA="-2.032"
Beta="1.334"
num_52WeekHigh="1.45"
num_52WeekLow="0.366"
num_50DayMovingAverage="0.806"
num_200DayMovingAverage="0.783"
SharesOutstanding="52315000"
DividendDate="None"
ExDividendDate="None"
symbol="SABS"
open="0.60"
high="0.69"
low="0.58"
price="0.68"
volume="31042.00"
latest_trading_day="2023-08-29"
previous_close="0.61"
change="0.08"
change_percent="12.3520%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="33"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="67"
Volume_recent_avg="878751"
Change_recent_avg="0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="0.2"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="67"
Aroon_momentum_negative="33"
image_negative_thumbnail_id_1="1157"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0191.jpeg"
image_negative_thumbnail_id_2="520"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0085.jpeg"
image_neutral_thumbnail_id_1="560"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_neutral_thumbnail_id_2="548"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0051.jpeg"
image_positive_thumbnail_id_1="656"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0052.jpeg"
image_positive_thumbnail_id_2="605"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0103.jpeg"
image_professor_thumbnail_id_1="1203"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
image_professor_thumbnail_id_2="1204"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0038.jpeg"
